Literature DB >> 20680803

Small-molecule modulators of c-Myc/Max and Max/Max interactions.

Thorsten Berg1.   

Abstract

The transcription factor c-Myc is overexpressed in many tumors in human beings and has been identified as a highly promising target for cancer therapy. Most biological functions of c-Myc require heterodimerization with its activation partner Max. Inhibition of the protein-protein interactions between c-Myc and Max by small molecules has been shown to be a feasible and powerful approach toward the inhibition of c-Myc functions. More recently, stabilization of Max homodimers to reduce the amount of Max available for activating c-Myc has also been demonstrated to counteract Myc activity. This review summarizes our current knowledge on small organic molecules that inhibit c-Myc by modulating protein-protein interactions relevant for the biological function of this important oncoprotein.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20680803     DOI: 10.1007/82_2010_90

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.291


  28 in total

Review 1.  Targeting DNA polymerase ß for therapeutic intervention.

Authors:  Eva M Goellner; David Svilar; Karen H Almeida; Robert W Sobol
Journal:  Curr Mol Pharmacol       Date:  2012-01       Impact factor: 3.339

Review 2.  The role of HTS in drug discovery at the University of Michigan.

Authors:  Martha J Larsen; Scott D Larsen; Andrew Fribley; Jolanta Grembecka; Kristoff Homan; Anna Mapp; Andrew Haak; Zaneta Nikolovska-Coleska; Jeanne A Stuckey; Duxin Sun; David H Sherman
Journal:  Comb Chem High Throughput Screen       Date:  2014-03       Impact factor: 1.339

3.  Intracellular Signaling Pathways in Rheumatoid Arthritis.

Authors:  Charles J Malemud
Journal:  J Clin Cell Immunol       Date:  2013-08-19

4.  A quantitative, surface plasmon resonance-based approach to evaluating DNA binding by the c-Myc oncoprotein and its disruption by small molecule inhibitors.

Authors:  Huabo Wang; Anand Ramakrishnan; Steven Fletcher; Edward V Prochownik
Journal:  J Biol Methods       Date:  2015

Review 5.  Prospects on strategies for therapeutically targeting oncogenic regulatory factors by small-molecule agents.

Authors:  Chih-Chien Chou; Santosh B Salunke; Samuel K Kulp; Ching-Shih Chen
Journal:  J Cell Biochem       Date:  2014-04       Impact factor: 4.429

6.  Inhibition of p53 DNA binding by a small molecule protects mice from radiation toxicity.

Authors:  Qingliang Li; Rezaul M Karim; Mo Cheng; Mousumi Das; Lihong Chen; Chen Zhang; Harshani R Lawrence; Gary W Daughdrill; Ernst Schonbrunn; Haitao Ji; Jiandong Chen
Journal:  Oncogene       Date:  2020-06-17       Impact factor: 9.867

7.  Inhibitor of MYC identified in a Kröhnke pyridine library.

Authors:  Jonathan R Hart; Amanda L Garner; Jing Yu; Yoshihiro Ito; Minghao Sun; Lynn Ueno; Jin-Kyu Rhee; Michael M Baksh; Eduard Stefan; Markus Hartl; Klaus Bister; Peter K Vogt; Kim D Janda
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-11       Impact factor: 11.205

8.  Anticancer targets in the glycolytic metabolism of tumors: a comprehensive review.

Authors:  Paolo E Porporato; Suveera Dhup; Rajesh K Dadhich; Tamara Copetti; Pierre Sonveaux
Journal:  Front Pharmacol       Date:  2011-08-25       Impact factor: 5.810

9.  The impact of small molecule binding on the energy landscape of the intrinsically disordered protein C-myc.

Authors:  Julien Michel; Rémi Cuchillo
Journal:  PLoS One       Date:  2012-07-16       Impact factor: 3.240

10.  c-MYC is a radiosensitive locus in human breast cells.

Authors:  M A Wade; N J Sunter; S E Fordham; A Long; D Masic; L J Russell; C J Harrison; V Rand; C Elstob; N Bown; D Rowe; C Lowe; G Cuthbert; S Bennett; S Crosier; C M Bacon; K Onel; K Scott; D Scott; L B Travis; F E B May; J M Allan
Journal:  Oncogene       Date:  2014-12-22       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.